PTX — Prescient Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- AU$37.85m
- AU$29.48m
- AU$0.69m
- 64
- 14
- 78
- 54
Annual cashflow statement for Prescient Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 1.75 | 1.15 | 1.46 | 2.04 | 3.13 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.32 | -3.97 | -4.31 | -6.19 | -7.4 |
| Capital Expenditures | — | -0.002 | -0.004 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -16 | 12 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | -0.002 | -0.004 | -16 | 12 |
| Financing Cash Flow Items | 0 | -0.837 | 0 | -0.698 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0 | 12.7 | 0.428 | 15.8 | 0.018 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.28 | 8.74 | -3.83 | -6.37 | 4.6 |